Lung

This miRNA signature was able to identify the presence of aggressive lung cancer not only in tumor, but also in normal lung tissues and in plasma samples of patients. Moreover, miRNAs deregulated in plasma samples collected before clinical appearance of disease were powerful molecular predictors of high-risk disease development.

Identifier RDF Subject URI of this object

QA State The current status with regard to quality assurance of this object.

Phase The current phase of the biomarker's development with regard to this organ.

Protocols Protocols (and studies) that are studying this object.

Publications Publications that have been written discussing this object.

Resources Additional resources about this object.

Datasets Datasets providing measured scientific bases for this biomarker.

Performance Comment A short summary of the biomarker performance with respect to a specific organ

The signature for risk for lung cancer could discriminate correctly 18 of 20 samples from subjects developing lung cancer in the training set (90% sensitivity) and resulted positive in only 1 of the 5 control pools (80% specificity). In the validation set, this signature identified 12 of 15 samples collected before lung cancer detection by spiral-CT, with sensitivity of 80%and specificity of 90% (AUC-ROC = 0.85, P < 0.0001; Fig. 4A). The predictive value of this signature was evaluated to be useful up to 28 mo before the disease, and mir-660, mir-140-5p, mir 451, mir-28-3p, mir-30c, and mir-92a are the most frequently deregulated miRNAs.

Organ The organ for which the biomarker indicates diseases.

CLIA Certification

FDA Certification

Contents

There are currently no items in this folder.